Polar Capital Holdings Plc Reports 5.0% Stake in Celldex Therapeutics

TL;DR

**Polar Capital just revealed a 5% stake in Celldex, signaling institutional confidence.**

AI Summary

Polar Capital Holdings Plc, a UK-based investment firm, reported on February 13, 2024, that it beneficially owned 3,369,825 shares of Celldex Therapeutics, Inc. common stock as of December 31, 2023. This represents 5.0% of Celldex's outstanding shares. This matters to investors because it signals a significant institutional investor has taken a notable stake in Celldex, potentially indicating confidence in the company's future prospects.

Why It Matters

A major institutional investor, Polar Capital Holdings Plc, has disclosed a 5.0% ownership stake in Celldex Therapeutics, which could be seen as a vote of confidence in the company's value and future growth.

Risk Assessment

Risk Level: low — This filing indicates a significant institutional investment, which generally reduces perceived risk by showing external validation of the company's potential.

Analyst Insight

A smart investor would view this as a positive signal, suggesting that a large institutional investor sees value in Celldex Therapeutics. It might prompt further research into Celldex's fundamentals and future prospects, especially its pipeline and clinical trial progress, to understand what attracted Polar Capital.

Key Numbers

• 3,369,825 — Shares Beneficially Owned (The total number of Celldex Therapeutics shares Polar Capital Holdings Plc reported owning.)
• 5.0% — Ownership Percentage (The percentage of Celldex Therapeutics' common stock that Polar Capital Holdings Plc now beneficially owns.)
• December 31, 2023 — Reporting Date (The specific date as of which Polar Capital Holdings Plc's ownership stake is being reported.)

Key Players & Entities

• Polar Capital Holdings Plc (company) — the reporting person and institutional investor
• Celldex Therapeutics, Inc. (company) — the subject company whose stock was purchased
• 3,369,825 (dollar_amount) — number of shares beneficially owned
• 5.0% (dollar_amount) — percentage of Celldex Therapeutics' common stock owned
• December 31, 2023 (person) — date of the event requiring the filing
• February 13, 2024 (person) — date the SC 13G filing was made

Forward-Looking Statements

• Other institutional investors may increase their positions in Celldex Therapeutics, following Polar Capital's lead. (Celldex Therapeutics, Inc.) — medium confidence, target: Q2 2024
• Celldex Therapeutics' stock price may experience a slight positive bump due to increased institutional interest. (Celldex Therapeutics, Inc.) — low confidence, target: February 2024

FAQ

Filing Documents

• polar-cldx123123.htm (SC 13G) — 84KB
• 0001172661-24-000763.txt ( ) — 86KB

(a)Name of Issuer

Item 1. (a)Name of Issuer CELLDEX THERAPEUTICS, INC.

(b)Address of Issuer’s Principal

Item 1. (b)Address of Issuer’s Principal Executive Offices Perryville III Building 53 Frontage Road, Suite 220 Hampton, New Jersey 08827

(a)Name of Person Filing

Item 2. (a)Name of Person Filing: Polar Capital Holdings Plc Polar Capital LLP

(b,) Address of Principal Business Office

Item 2. (b,) Address of Principal Business Office: 16 Palace Street London, SW1E 5JD

(c)Citizenship

Item 2. (c)Citizenship: United Kingdom

(d)Title of Class of Securities

Item 2. (d)Title of Class of Securities Common Stock, par value $.001 (the “Shares”)

(e) CUSIP No

Item 2. (e) CUSIP No.: 15117B202 CUSIP No. 15117B202 SCHEDULE 13G Page 5 of 8 Pages

If

Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) x An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) x A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) o A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) A group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: CUSIP No. 15117B202 SCHEDULE 13G Page 6 of 8 Pages Item 4.Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1: Polar Capital Holdings Plc (a) Amount beneficially owned: 3,135,871 (b) Percent of class: 5.73%* (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 3,135,871 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 3,135,871 (iv) Shared power to dispose or to direct the disposition of: 0 Polar Capital LLP (a) Amount beneficially owned: 3,135,871 (b) Percent of class: 5.73%* (c) Number o

View Full Filing

View this SC 13G filing on SEC EDGAR